Effects of silymarin and silymarin-doxorubicin applications on telomerase activity of human hepatocellular carcinoma cell line HepG2

Journal of B.U.ON.

Volumn 20, Issue 2, 2015, Pages 555-561

  Yurtcu, Erkan ^a   Iseri, Ozlem Darcansoy ^a   Sahin, Feride Iffet ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Checkerboard; Doxorubicin; Hepatocellular carcinoma; Silymarin; Telomerase activity

Indexed keywords

DOXORUBICIN; SILYMARIN; TELOMERASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL LYSATE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; LIPID OXIDATION; LIPID PEROXIDATION; MCF 7 CELL LINE; MINIMUM INHIBITORY CONCENTRATION; MTT ASSAY; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; ENZYMOLOGY; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; HEP G2 CELLS; HUMANS; LIPID PEROXIDATION; LIVER NEOPLASMS; SILYMARIN; TELOMERASE;

EID: 84930743891     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Zhang B, Qian D, Ma HH et al. Anthracyclines disrupt telomere maintenance by telomerase through inducing Pin Xl ubiquitination and degradation. Oncogene 2012; 5:1-12.
2. Wysocki PJ. Targeted therapy of hepatocellular cancer. Expert Opin Investig Drugs 2010; 19:265-274.
3. Jin C, Li H, He Y et al. Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo. J Cancer Res Clin Oncol 2010; 136:267-274.
4. Riddick DS, Lee C, Ramji S et al. Cancer chemotherapy and drug metabolism. Drug Metab Dispos 2005; 33:1083-1096.
5. Robert J, Larsen AK. Drug resistance to topoisomerase II inhibitors. Biochimie 1998; 80:247-254.
6. Tao SF, Zhang CS, Guo XL et al. Anti-tumor effect of 5-aza-2'-deoxycytidine by inhibiting telomerase activity in hepatocellular carcinoma cells. World J Gastroenterol 2012; 21:2334-2343.
7. Tahara H, Nakanishi T, Kitamoto M et al. Telomerase activity in human liver tissues: comparison between chronic liver disease and hepatocellular carcinomas. Cancer Res 1995; 55:2734-2736.
8. Nakashio R, Kitamoto M, Tahara H., Nakanishi T, Ide T, Kajiyama G. Significance of telomerase activity in the diagnosis of small differentiated hepatocellular carcinoma. Int J Cancer 1997; 74:141-147.
9. Lee KH, Rudolph KL, Ju YJ et al. Telomere dysfunction alters the chemotherapeutic profile of transformed cells. Proc Natl Acad Sci 2001; 13:3381-3386.
10. Ramasamy K, Agarwal R. Multitargeted therapy of cancer by Silymarin. Cancer Lett 2008; 269:352-362.
11. Yurtcu E, Kasapoglu E, Sahin FI. Protective effects of b-carotene and Silymarin on human lymphocytes. Turk J Biol 2012; 36:47-52.
12. Huber A, Thongphasuk P, Erben G et al. Significantly greater antioxidant anticancer activities of 2, 3-de-hydrosilybin than silybin. Biochem Biophys Acta 2008; 1780: 837847.
13. Kars MD, Iseri OD, Gunduz U, Ural A.U., Arpaci F., Molnar J. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. Anticancer Res 2006; 26:4559-4568.
14. Eliopoulos GM, Moellering RC. Antimicrobial combinations. In: Lorian V (Ed): Antibiotics in Laboratory Medicine. Williams and Wilkins, USA, 1980, pp 432-443.
15. Ahn DU, Olson DG, Jo C et al. Effect of muscle type, packaging, and irradiation on lipid oxidation, volatile production, and color in raw pork patties. Meat Sci 1998; 49:27-39.
16. Bradford MM. Rapid and sensitive method for quantitation of microgram quantities of protein utilizing principle of protein-dye binding. Ann Biochem 1976; 72:248-254.
17. Herbert BS, Hochreiter AE, Wright W.E., Shay JW. Nonradioactive detection of telomerase activity using the telomeric repeat amplification protocol. Nat Protoe 2006; 1:1583-1590.
18. Eskiocak U, Iseri OD, Kars M.D., Bicer A., Gunduz U. Effect of doxorubicin on telomerase activity and ap-optotic gene expression in doxorubicin-resistant and -sensitive MCF-7 cells: an experimental study. Chemotherapy 2008; 54:209-216.
19. Bassam BJ, Caetano-Anolles G, Gresshoff PM. Fast and sensitive silver staining of DNA in Polyacrylamide gels. Ann Biochem 1991; 196:80-83.
20. Walker PR, Smith C, Youdale T., Leblanc J, Whitfield JF, Sikorska M. Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes. Cancer Res 1991; 51:1078-1085.
21. Kwok TT, Mok CH, Menton-Brennan L. Up-regulation of a mutant form of p53 by doxorubicin in human squamous carcinoma cells. Cancer Res 1994; 54:2834-2836.
22. Rastegar H, Ahmadi Ashtiani H, Anjarani S, Bokaee S., Khaki A, Javadi L. The role of milk thistle extract in breast carcinoma cell line (MCF-7) apoptosis with doxorubicin. Acta Med Iran 2013; 51:591-598.
23. Tyagi AK, Singh RP, Agarwal C, Chan D.C., Agarwal R. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis. Clin Cancer Res 2002; 8:3512-3519.
24. Tyagi AK, Agarwal C, Chan DC et al. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Rep 2004; 11:493-499.
25. Sadava D, Kane SE. Silibinin reverses drug resistance in human small-cell lung carcinoma cells. Cancer Lett 2013; 339:102-106.
26. Colombo V, Lupi M, Falcetta F., Forestieri D, D'Incalci M, Ubezio P. Chemotherapeutic activity of Silymarin combined with doxorubicin or paclitaxel in sensitive and multidrug-resistant colon cancer cells. Cancer Chemother Pharmacol 2011; 67:369-379.
27. Wen Z, Dumas TE, Schrieber S.J., Hawke RL, Fried MW, Smith PC. Pharmacokinetics and metabolic profile of free, conjugated, and total Silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metabol Disposit 2008; 36:65-72.
28. Wege H, Brümmendorf TH. Telomerase activation in liver regeneration and hepatocarcinogenesis: Dr. Jeky-11 or Mr. Hyde? Curr Stem Cell Res Ther 2007; 2:31-38.
29. Zhu X, Kumar R, Mandai M et al. Cell cycle - dependent modulation of telomerase activity in tumor cells. Proc Natl Acad Sci USA 1996; 93:6091-6095.
30. Ku WC, Cheng AJ, Wang TCV. Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture. Biochem Biophy Res Comm 1997; 241:730-736.
31. Burger AM, Double JA, Newell DR. Inhibition of telomerase activity by cisplatin in human testicular cancer cells. Eur J Cancer 1997; 33:638-644.
32. Li P, Hou M, Lou F., Björkholm M, Xu D. Telomere dysfunction induced by chemotherapeutic agents and radiation in normal human cells. Int J Biochem Cell Biol 2012; 44:1531-1540.
33. Saretzki G. Telomerase inhibition as cancer therapy. Cancer Lett 2003; 194:209-219.
34. Zhang RG, Guo LX, Wang XW et al. Telomerase inhibition and telomere loss in BEL-7404 human hepatoma cells treated with doxorubicin. World J Gastroenterol 2002; 8:827-831.
35. Nasiri M, Zarghami N, Koshki KN et al. Curcumin and silibinin inhibit telomerase expression in T47D human breast cancer cells. Asian Pac J Cancer Prev 2013; 14:3449-3453.
36. Thelen P, Wuttke W, Jarry H., Grzmil M, Ringert RH. Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells. J Urol 2004; 171:1934-1938.
37. Ebrahimnezhad Z, Zarghami N, Keyhani M et al. Inhibition of hTERT Gene Expression by Silibinin-Loaded PLGA-PEG-Fe304 in T47D Breast Cancer Cell Line. Bioimpacts 2013; 3:67-74.
38. Faezizadeh Z, Mesbah-Namin SA, Allameh A. The effect of Silymarin on telomerase activity in the human leukemia cell line K562. Planta Med 2012; 78:899-902.
39. Vacek J, Zatloukalova M, Desmier T et al. Antioxidant, metal-binding and DNA-damaging properties of flavonolignans: a joint experimental and computational highlight based on 7-O-galloylsilybin. Chem Biol Interact 2013; 205:173-180.
40. Fritz KS, Petersen DR. Exploring the biology of lipid peroxidation-derived protein carbonylation. Chem Res Toxicol 2011; 19; 24:1411-1419.
41. Yurtcu E, Iseri O, Sahin F. Genotoxic and cytotoxic effects of doxorubicin and Silymarin on human hepatocellular carcinoma cells. Hum Exp Toxicol 2014; 33:1269-1276.